HC Wainwright Has Bullish Estimate for ENTA Q2 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of Enanta Pharmaceuticals in a report issued on Tuesday, February 10th. HC Wainwright analyst B. Folkes now forecasts that the biotechnology company will post earnings of ($0.51) per share for the quarter, up from their previous estimate of ($0.54). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.73) EPS, FY2027 earnings at ($2.53) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($2.40) EPS and FY2030 earnings at ($2.19) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. The firm had revenue of $18.62 million for the quarter, compared to analyst estimates of $16.14 million.

A number of other research analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They set an “overweight” rating and a $17.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Trading Down 2.9%

Shares of Enanta Pharmaceuticals stock opened at $13.84 on Thursday. The stock has a market capitalization of $401.64 million, a price-to-earnings ratio of -4.33 and a beta of 0.98. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.15. The business’s 50 day simple moving average is $14.10 and its 200-day simple moving average is $11.42.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of ENTA. CWM LLC lifted its holdings in shares of Enanta Pharmaceuticals by 22.1% in the second quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 3,879 shares during the period. Bank of Montreal Can grew its holdings in Enanta Pharmaceuticals by 32.8% during the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock worth $256,000 after acquiring an additional 8,365 shares during the period. Man Group plc bought a new stake in Enanta Pharmaceuticals in the third quarter worth about $481,000. Invesco Ltd. lifted its holdings in Enanta Pharmaceuticals by 4.3% in the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 2,607 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in Enanta Pharmaceuticals by 119.7% in the 4th quarter. MetLife Investment Management LLC now owns 14,408 shares of the biotechnology company’s stock valued at $227,000 after acquiring an additional 7,849 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $29,968.38. Following the transaction, the insider owned 30,620 shares of the company’s stock, valued at approximately $435,722.60. This trade represents a 6.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Yat Sun Or sold 2,390 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $34,009.70. Following the transaction, the insider owned 371,392 shares in the company, valued at $5,284,908.16. This represents a 0.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 11,961 shares of company stock worth $170,149 in the last 90 days. Corporate insiders own 11.48% of the company’s stock.

Trending Headlines about Enanta Pharmaceuticals

Here are the key news stories impacting Enanta Pharmaceuticals this week:

• Positive Sentiment: Zacks upgraded ENTA to a Zacks Rank #2 (Buy), a near‑term bullish signal that can attract momentum traders and retail investors. Zacks Upgrade
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $20 price target and raised several medium‑ and long‑term EPS forecasts (FY2027–FY2030 and multiple quarters), which supports a constructive longer‑term thesis. HC Wainwright Note (MarketBeat)
• Positive Sentiment: An AAII writeup highlighted reasons the stock recently rallied (article framed why ENTA was up ~6%), which can amplify retail interest and explain recent intraday volatility. AAII: Why ENTA Is Up
• Neutral Sentiment: Short‑interest reports flagged a “large increase” in February but the published figures show 0 shares and NaN changes — indicating a likely data/reporting error. The ambiguous short‑interest read reduces clarity about bearish positioning and is unlikely by itself to explain a sustained move. (No external link available)
• Negative Sentiment: Within HC Wainwright’s update, the firm lowered its Q4 2026 EPS estimate (from ($0.56) to ($0.73)), a near‑term negative revision that could pressure sentiment despite the firm’s overall Buy stance and higher multi‑year estimates. HC Wainwright Note (MarketBeat)

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.